Researchers discovered that the CYLD protein turns off pathogen-induced inflammatory responses mediated by the myeloid differentiation factor 88 (MyD88), thereby preventing uncontrolled inflammation from damaging tissues and eventually inducing chronic obstructive pulmonary disease (COPD). The study, titled “Deubiquitinase CYLD acts as a negative regulator for bacterium NTHi-induced inflammation…
News
GCE Healthcare recently announced the launch of the Zen-O portable oxygen concentrator (POC), a device designed to help patients with respiratory conditions, including chronic obstructive pulmonary disease (COPD), to better manage their oxygen therapy inside or outside the home. The device is the first product to be developed at GCE’s new manufacturing…
Scientists have created a model of the human small airway using organ-on-a-chip technology that can help researchers study inflammatory lung diseases like chronic obstructive pulmonary disease (COPD) and asthma outside a patient’s body, and potentially makes it possible to more easily identify new biomarkers and evaluate drug candidates. The study, by researchers at the Harvard John A.
A new study revealed that corticosteroid treatment in patients with chronic obstructive pulmonary disease (COPD) or asthma increases their risk of developing a specific form of lung cancer – squamous cell carcinoma. The study, “The use of corticosteroids in patients with COPD or asthma does not decrease lung squamous…
Inova Labs Inc., a company dedicated to medical devices for the treatment of respiratory conditions including chronic obstructive pulmonary disease (COPD), recently received the New Product Award 2015 for its oxygen concentrator system Activox DUO2™. The award was given by HME Business, part of the HME Media Group, which…
LifeMap Solutions recently announced that its free iOS app, COPD Navigator is now available for download on iTunes. An enhanced version branded as SuperCare iBreathe, deployed by SuperCare Health, will also soon be released. LifeMap, a digital-health arm of BioTime, Inc., developed the app in close…
A dossier assessment developed by the German Institute for Quality and Efficiency in Health Care (IQWiG) examined the added benefit of the fixed-dose combination therapy tiotropium plus olodaterol (Spiolto Respimat), approved this year for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. The study compared tiotropium/olodaterol…
The Lung Association in Canada, as part of its Breathing as One research campaign, and Aeri Health, a company from Vancouver specialized in health management, have partnered to launch a novel mobile app for patients with chronic obstructive pulmonary disease (COPD). According to a news release, the app…
Nonin Medical, the developer of the finger pulse oximeter and a leader in designing and manufacturing non-invasive medical monitoring, recently announced a collaboration with Tri-anim Health Services to bring Nonin’s new COPD STEP™ (Seamless Treatment and Exacerbation Prevention) Plan to hospitals in the United States commencing this November. The announcement…
Novartis recently announced that the company’s once-a-day Ultibro® Breezhaler® (indacaterol/glycopyrronium), a dual bronchodilator, has meet its primary endpoint in a Phase 3 clinical trial (FLAME trial), showing superior efficacy when compared to twice-a-day Seretide® (salmeterol/fluticasone) in reducing mild, moderate and severe chronic obstructive pulmonary disease (COPD) exacerbations. The IGNITE Phase…
Recent Posts
- Redrawing the geography of my life one breath at a time
- A diagnosis is a map that shows our way through an unknown land
- US study names COPD therapy Anoro Elipta top choice for new patients
- Applying wise old sayings to a different body with COPD
- I maintain my morning rituals to keep COPD from shrinking my world